Kairos Pharma Files 2025 Proxy Statement
Ticker: KAPA · Form: DEF 14A · Filed: May 1, 2025 · CIK: 1962011
Sentiment: neutral
Topics: proxy-statement, annual-filing, governance
TL;DR
Kairos Pharma (KRP) filed its DEF 14A proxy statement. Standard annual disclosure.
AI Summary
Kairos Pharma, LTD. filed its definitive proxy statement (DEF 14A) on May 1, 2025, for the fiscal year ending December 31, 2024. The company, incorporated in Delaware and headquartered in Los Angeles, CA, operates in the Pharmaceutical Preparations sector. This filing is a routine disclosure related to shareholder matters.
Why It Matters
This filing provides shareholders with essential information regarding company governance and matters to be voted on at the upcoming shareholder meeting, impacting their investment decisions.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) and does not contain new material financial information or strategic changes.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the proxy statement.)
- 20250501 — Filing Date (Date the definitive proxy statement was filed with the SEC.)
Key Players & Entities
- Kairos Pharma, LTD. (company) — Registrant
- 0001962011 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
- 03 Life Sciences (company) — Organization Name
- 462993314 (company) — EIN
- DE (company) — State of Incorporation
- 2355 WESTWOOD BLVD. #139 (company) — Business Address
- LOS ANGELES (company) — City
- CA (company) — State
- 90064 (company) — ZIP Code
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit proxies from shareholders for an upcoming annual or special meeting. It provides detailed information about the matters to be voted on, such as director elections, executive compensation, and other corporate proposals.
What is Kairos Pharma, LTD.'s fiscal year end?
Kairos Pharma, LTD.'s fiscal year ends on December 31st, as indicated in the filing.
When was this DEF 14A filed?
This Definitive Proxy Statement (DEF 14A) was filed on May 1, 2025.
What industry does Kairos Pharma, LTD. operate in?
Kairos Pharma, LTD. operates in the Pharmaceutical Preparations industry, with a Standard Industrial Classification code of 2834.
Where is Kairos Pharma, LTD. headquartered?
Kairos Pharma, LTD. is headquartered in Los Angeles, CA, with a business address at 2355 Westwood Blvd. #139.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 1, 2025 regarding Kairos Pharma, LTD. (KAPA).